NLRP3 and Alzheimer disease: In this section, we describe the NLR family, the NLRP3 inflammasome activation pathway, evidence that NLRP3 inflammasome activity may worsen AD pathology, and progress made to develop therapeutic agents targeted at reducing activation of the NLRP3 inflammasome.